Stock Analysis of Cellectis SA (CLLS)

Loading ...

Birds's Eye

Stock Analysis of Cellectis SA (CLLS) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	CLLS
Close	2.99
Change	-0.0499 / 1.64 %
Volume	28205.00
Vol Change	12962.00 / 85.04 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Mild Bullish
Growth Index	Poor Growth Stock
Value Index	Very Low Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Very Low Stability Stock

Fundamental View of Cellectis SA

PE (TTM)

-1.67

Very Poor

Price / Book

2.06

Indecisive

Price / Sales

211.61

Very Poor

Piotroski F Score

2.0

Poor

Market Cap

215146 K

Enterprise Value

120546 K

All Financial Ratio's

ROA (TTM)

-41.94

Very Poor

ROE (TTM)

-124.89

Very Poor

Net Margin (TTM)

-12664.52

Very Poor

Revenue

13.95 %

16496.00 K

Net Profit

13.86 %

-85010.00 K

Debt to Equity

0.497

Very Good

Altman Z Score

-1.65

Very Poor

Quick Ratio

0

Poor

Cash Ratio

1.31

Indecisive

Financial Statement Analysis

Highs/Lows of Cellectis SA

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	3.06	2.29 %	1.54 %	3.1	2.874	15-May-24	17-May-24
Two Week	2.99	0 %	3.42 %	3.38	2.874	06-May-24	17-May-24
One Month	2.46	21.54 %	5.60 %	3.38	2.3	06-May-24	18-Apr-24
Three Month	2.89	3.46 %	5.95 %	3.38	2.3	06-May-24	18-Apr-24
Six Months	2.93	2.05 %	17.48 %	3.7735	2.3	20-Dec-23	18-Apr-24
One year	1.8	66.11 %	27.52 %	3.7735	0.9628	20-Dec-23	26-Oct-23
Two year	3.48	14.08 %	29.70 %	4.04	0.9628	17-Jan-23	26-Oct-23
Five year	18.67	83.99 %	85.46 %	4.04	0.9628	17-Jan-23	26-Oct-23

Technical View of Cellectis SA

RSI

55.07

Neutral

MACD

0.112

Bullish

ADX

23.64

Neutral

Super Trend

2.65

Mild Bullish

Williams %R

-44.32

Neutral

CCI

28.84

Neutral

Technical Analysis Deep Dive

EMA 5

3.03

Bearish

EMA 15

2.96

Bullish

EMA 50

2.80

Bullish

EMA 100

2.72

Mild Bullish

SMA 100

2.80

Strong Bullish

SMA 200

2.44

Strong Bullish

SMA 5 / 20

3.02 / 2.87

Bullish

SMA 15 / 50

2.97 / 2.70

Strong Bullish

SMA 50 / 200

2.70 / 2.44

Bullish

MA Analysis Deep Dive

Charts of Cellectis SA

Returns of Cellectis SA with Peers

Period / Stock	CLLS	IPHA	KMPH	INMB
1 Week	-2.29%	7.11%	12.12%	8.28%
1 Mth	21.54%	12.44%	52.30%	28.71%
3 Mth	3.46%	6.69%	13.95%	-22.56%
6mth	2.05%	10.61%	5.01%	46.42%
1 Year	66.11%	-10.27%	37.34%	46.42%
2 Year	-14.08%	-11.73%	-27.28%	44.86%
5 Years	-83.99%	-	-93.95%	0.277%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Cellectis SA with Peers

Ratio / Stock	CLLS	IPHA	KMPH	INMB
PE	-1.67	-2.69	-5.46	3818.41
P/B	2.06	4.04	2.30	2237.87
ROA	-41.94	-41.33	-33.53	41.20
ROE	-124.89	-150.51	-42.06	59.27
Debt To Equity	0.497	0.762	0.205	0.269
Revenue	16496.00 K 13.95 %	51901.00 K 4.56 %	10458.00 K 63.50 %	224000 159.89 %
Net Income	-85010.00 K 13.86 %	-7570.00 K 86.97 %	-41543.00 K 385.60 %	-27433.00 K 0.491 %

Technicals of Cellectis SA with Peers

Technical / Stock	CLLS	IPHA	KMPH	INMB	-
ADX	23.64	19.69	27.24	15.20
CMF	0.496	0.531	0.063	0.115
MFI	67.95	51.18	65.77	43.72
RSI	55.07	57.79	70.95	50.38
MACD Abv Signal	True	True	True	True
Price Above 50 MA	True	True	True	False	-
Price Above 200 MA	True	True	True	True	-

About : Cellectis SA

Address : 8, rue de la Croix Jarry, Paris, France, 75013
Tel : 33 1 81 69 16 00
URL : https://www.cellectis.com
Code : CLLS, ISIN : US15117K1034, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_Feb_2007

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Note : All Data Generated at the End of Trading Hours (EOD Data)